E-051 Disparities in stroke: Associating socioeconomic factors with ischemic stroke outcome

in the ATLAS IDE trial (Investigational Device Exemption) were identified. The primary efficacy end point was complete aneurysm occlusion (Raymond-Roy class 1) on 12-month angiography, in the absence of retreatment or parent artery stenosis (>50%) at the target location. The primary safety end point was any major stroke or ipsilateral stroke or neurological death within 12 months. Adjudication of the primary end points was performed by an independent Imaging Core Laboratory and the Clinical Events Committee. Result A total of 60 patients of were identified. The mean age was 59 and 28.3% were men. The median aneurysm size was 6.7mm with a median neck size of 4.3 mm. Aneurysm locations were as follows: basilar apex (56.7%), basilar trunk (3.3%), anterior communicating artery (20%), anterior cerebral artery (3.3%), internal cerebral artery (3.3%) and middle cerebral artery (13.3%). The composite primary efficacy end point of complete aneurysm occlusion (Raymond-Roy 1) without parent artery stenosis or aneurysm retreatment was achieved in 81.1% of patients. Overall, 1.7% (1/60) of patients experienced a primary safety end point of major ipsilateral stroke or neurological death. Conclusions In the ATLAS IDE aneurysm cohort premarket approval study, the Neuroform Atlas stent with adjunctive Ystent coiling met the primary end points and demonstrated high rates of long-term complete aneurysm occlusion at 12 months, with low rates of morbidity. Disclosures A. Jadhav: None. S. Desai: None. R. Hanel: None. D. Frei: None. A. Khaldi: None. S. Hetts: None. O. Zaidat: None. B. Jankowitz: None.